Based on the differences in timing, location, and nonoverlapping effects of the two immune checkpoint pathways, including PD-1/PD-L1 and CTLA-4 immune checkpoints, combining different ICIs may act synergistically in the treatment of HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.